Arcutis Biotherapeutics Inc. (ARQT): Price and Financial Metrics
ARQT Price/Volume Stats
Current price | $9.91 | 52-week high | $15.40 |
Prev. close | $9.59 | 52-week low | $1.76 |
Day low | $9.61 | Volume | 3,723,620 |
Day high | $10.02 | Avg. volume | 5,176,643 |
50-day MA | $8.28 | Dividend yield | N/A |
200-day MA | $6.42 | Market Cap | 959.42M |
ARQT Stock Price Chart Interactive Chart >
ARQT POWR Grades
- Value is the dimension where ARQT ranks best; there it ranks ahead of 82.96% of US stocks.
- ARQT's strongest trending metric is Value; it's been moving up over the last 26 weeks.
- ARQT ranks lowest in Stability; there it ranks in the 5th percentile.
ARQT Stock Summary
- With a price/sales ratio of 7.53, ARCUTIS BIOTHERAPEUTICS INC has a higher such ratio than 85.87% of stocks in our set.
- Revenue growth over the past 12 months for ARCUTIS BIOTHERAPEUTICS INC comes in at 6,664.28%, a number that bests 99.9% of the US stocks we're tracking.
- In terms of volatility of its share price, ARQT is more volatile than 94.12% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to ARCUTIS BIOTHERAPEUTICS INC, a group of peers worth examining would be PSTV, BIAF, GENE, TGTX, and SCYX.
- ARQT's SEC filings can be seen here. And to visit ARCUTIS BIOTHERAPEUTICS INC's official web site, go to www.arcutis.com.
ARQT Valuation Summary
- ARQT's price/sales ratio is 6.2; this is 181.82% higher than that of the median Healthcare stock.
- Over the past 48 months, ARQT's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for ARQT.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
ARQT | 2023-12-29 | 6.2 | 6.5 | -1.1 | -1.7 |
ARQT | 2023-12-28 | 6.4 | 6.7 | -1.2 | -1.7 |
ARQT | 2023-12-27 | 5.8 | 6.1 | -1.1 | -1.6 |
ARQT | 2023-12-26 | 6.0 | 6.3 | -1.1 | -1.6 |
ARQT | 2023-12-22 | 5.7 | 6.0 | -1.0 | -1.6 |
ARQT | 2023-12-21 | 5.0 | 5.3 | -0.9 | -1.4 |
ARQT's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ARQT has a Quality Grade of D, ranking ahead of 5.58% of graded US stocks.
- ARQT's asset turnover comes in at 0 -- ranking 441st of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows ARQT's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0 | NA | -0.704 |
2021-03-31 | 0 | NA | -1.018 |
2020-12-31 | 0 | NA | -1.219 |
2020-09-30 | 0 | NA | -1.692 |
2019-12-31 | 0 | NA | -1.758 |
ARQT Price Target
For more insight on analysts targets of ARQT, see our ARQT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $54.88 | Average Broker Recommendation | 1.44 (Moderate Buy) |
Arcutis Biotherapeutics Inc. (ARQT) Company Bio
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its piepline consists of topical treatments for plaque psoriasis, atopic dermatitis, eczema, vitiligo, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne on June 1, 2016 and is headquartered in Westlake Village, CA.
Latest ARQT News From Around the Web
Below are the latest news stories about ARCUTIS BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate ARQT as an investment opportunity.
The Zacks Analyst Blog Highlights Allogene Therapeutics, Arcutis Biotherapeutics and C4 TherapeuticsAllogene Therapeutics, Arcutis Biotherapeutics and C4 Therapeutics are part of the Zacks top Analyst Blog. |
3 Under-$10 Drug Stocks Wall Street Analysts Recommend BuyingWe present three small biotech stocks, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024 following signals of a stabilizing market. |
11 High Growth Micro-Cap Stocks to BuyIn this article, we discuss 11 high-growth micro-cap stocks to buy. To skip the detailed analysis and past performance of micro-cap stocks, go directly to the 5 High Growth Micro-cap Stocks to Buy. Shares of small companies with market capitalization usually between $50 to $300 million are considered micro-cap stocks. The risk in these investments […] |
Arcutis (ARQT) Up on FDA Nod for Zoryve in Seborrheic DermatitisThe FDA approves Arcutis' (ARQT) NDA for Zoryve topical foam 0.3% for treating seborrheic dermatitis in individuals nine years of age and above. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayIt's time to start the week with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Monday morning! |
ARQT Price Returns
1-mo | -6.77% |
3-mo | 206.81% |
6-mo | 86.63% |
1-year | -7.47% |
3-year | -62.76% |
5-year | N/A |
YTD | 206.81% |
2023 | -78.18% |
2022 | -28.64% |
2021 | -26.27% |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...